Literature DB >> 31372816

IgM ANCA in healthy individuals and in patients with ANCA-associated vasculitis.

L S Jeffs1, C A Peh2,3, A Nelson3,4, P G Tan5, E Davey5, K Chappell6, G B Perkins3, P R Hurtado2,3.   

Abstract

Low levels of IgM auto-antibodies have been reported in health and disease. IgM anti-neutrophil cytoplasmic antibodies (ANCA) have been reported in patients with ANCA-associated vasculitis (AAV). We sought to investigate if healthy individuals may have IgM ANCA in their sera. The first aim of the study was to determine whether IgM ANCA was present in healthy individuals and in patients with ANCA-associated vasculitis. The second aim was to determine what happens to IgM ANCA levels over time. The third aim was to determine whether bacterial infections affected IgM ANCA levels in non-AAV patients. Sera from healthy individuals and patients with AAV were tested for IgM ANCA by immunofluorescence on fixed neutrophils, immunoprecipitation, Western blot and ELISA. Peripheral blood mononuclear cells were isolated and tested by ELISpot for circulating IgM ANCA B cells. To determine whether infection affected IgM ANCA levels, we studied non-AAV patients with bacterial endocarditis or Staphylococcus aureus bacteraemia and measured IgM ANCA levels over time. IgM ANCA is detectable in both healthy individuals and patients with AAV and the titres decreased with increasing age. Circulating IgM ANCA B cells were identified by ELISpot. In the presence of infection, we could not find a significant change in IgM ANCA levels. We report the presence of low-level specific IgM ANCA in the sera of healthy individuals and in patients with ANCA-associated vasculitis. Bacterial infection did not affect the level of IgM ANCA in this small study.

Entities:  

Keywords:  ANCA-associated vasculitis (AAV); Anti-neutrophil cytoplasmic antibodies (ANCA); IgM ANCA; Myeloperoxidase (MPO); Proteinase-3 (PR3)

Mesh:

Substances:

Year:  2019        PMID: 31372816     DOI: 10.1007/s12026-019-09091-x

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  53 in total

1.  Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis.

Authors:  J S Li; D J Sexton; N Mick; R Nettles; V G Fowler; T Ryan; T Bashore; G R Corey
Journal:  Clin Infect Dis       Date:  2000-04-03       Impact factor: 9.079

Review 2.  Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'.

Authors:  S Avrameas
Journal:  Immunol Today       Date:  1991-05

3.  Microscopic polyangiitis following recurrent Staphylococcus aureus bacteremia and infectious endocarditis.

Authors:  J A Miranda-Filloy; J A Veiga; Y Juarez; C Gonzalez-Juanatey; M A Gonzalez-Gay; C Garcia-Porrua
Journal:  Clin Exp Rheumatol       Date:  2006 Nov-Dec       Impact factor: 4.473

4.  Chronic crusting, nasal carriage of Staphylococcus aureus and relapse rate in pulmonary Wegener's granulomatosis.

Authors:  K Zycinska; K A Wardyn; T M Zielonka; U Demkow; M S Traburzynski
Journal:  J Physiol Pharmacol       Date:  2008-12       Impact factor: 3.011

5.  Association of ANCA isotype and affinity with disease expression.

Authors:  V L Esnault; N Ronda; D R Jayne; C M Lockwood
Journal:  J Autoimmun       Date:  1993-04       Impact factor: 7.094

6.  Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis.

Authors:  C A Stegeman; J W Tervaert; W J Sluiter; W L Manson; P E de Jong; C G Kallenberg
Journal:  Ann Intern Med       Date:  1994-01-01       Impact factor: 25.391

7.  Determinants of renal outcome in anti-myeloperoxidase-associated necrotizing crescentic glomerulonephritis.

Authors:  C F Franssen; C A Stegeman; W W Oost-Kort; C G Kallenberg; P C Limburg; A Tiebosch; P E De Jong; J W Tervaert
Journal:  J Am Soc Nephrol       Date:  1998-10       Impact factor: 10.121

8.  Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group.

Authors:  C A Stegeman; J W Tervaert; P E de Jong; C G Kallenberg
Journal:  N Engl J Med       Date:  1996-07-04       Impact factor: 91.245

9.  IgA- and SIgA anti-PR3 antibodies in serum versus organ involvement and disease activity in PR3-ANCA-associated vasculitis.

Authors:  C Sandin; P Eriksson; M Segelmark; T Skogh; A Kastbom
Journal:  Clin Exp Immunol       Date:  2016-02-25       Impact factor: 4.330

10.  Passive immunization with hypochlorite-oxLDL specific antibodies reduces plaque volume in LDL receptor-deficient mice.

Authors:  Marcella van Leeuwen; Michael J Kemna; Menno P J de Winther; Louis Boon; Adriaan M Duijvestijn; Darius Henatsch; Nico A Bos; Marion J J Gijbels; Jan Willem Cohen Tervaert
Journal:  PLoS One       Date:  2013-07-16       Impact factor: 3.240

View more
  1 in total

Review 1.  Pathogenicity of Proteinase 3-Anti-Neutrophil Cytoplasmic Antibody in Granulomatosis With Polyangiitis: Implications as Biomarker and Future Therapies.

Authors:  Jérôme Granel; Brice Korkmaz; Dalila Nouar; Stefanie A I Weiss; Dieter E Jenne; Roxane Lemoine; Cyrille Hoarau
Journal:  Front Immunol       Date:  2021-02-18       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.